Your browser doesn't support javascript.
Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial.
Carrouel, Florence; Valette, Martine; Gadea, Emilie; Esparcieux, Aurélie; Illes, Gabriela; Langlois, Marie Elodie; Perrier, Hervé; Dussart, Claude; Tramini, Paul; Ribaud, Mélina; Bouscambert-Duchamp, Maude; Bourgeois, Denis.
  • Carrouel F; Laboratory "Systemic Health Care", EA4129, University of Lyon, University Claude Bernard Lyon 1, Lyon, France. Electronic address: florence.carrouel@univ-lyon1.fr.
  • Valette M; Virology Laboratory, Institute of Infectious Agents, National Center for Virus of Respiratory Infections, Croix-Rousse Hospital, Hospices Civils of Lyon, Lyon, France.
  • Gadea E; Equipe SNA-EPIS, EA4607, University Jean Monnet, Saint-Etienne, France; Clinical Research Unit, Emile Roux Hospital Centre, le Puy-en-Velay, France.
  • Esparcieux A; Department of Internal Medicine and Infectious Diseases, Protestant Infirmary, Caluire-et-Cuire, France.
  • Illes G; Department of Internal Medicine and Infectious Diseases, Intercommunal Hospital Centre of "Mont de Marsan et du Pays des Sources", Mont de Marsan, France.
  • Langlois ME; Department of Internal Medicine and Infectious Diseases, Saint Joseph Saint Luc Hospital, Lyon, France.
  • Perrier H; Clinical Research Unit, Protestant Infirmary, Lyon, France.
  • Dussart C; Laboratory "Systemic Health Care", EA4129, University of Lyon, University Claude Bernard Lyon 1, Lyon, France.
  • Tramini P; Department of Public Health, Faculty of Dental Medicine, University of Montpellier, Montpellier, France.
  • Ribaud M; National Institute of Agronomic Research (INRAE), BioSP, UR546, Avignon, France.
  • Bouscambert-Duchamp M; Virology Laboratory, Institute of Infectious Agents, National Center for Virus of Respiratory Infections, Croix-Rousse Hospital, Hospices Civils of Lyon, Lyon, France.
  • Bourgeois D; Laboratory "Systemic Health Care", EA4129, University of Lyon, University Claude Bernard Lyon 1, Lyon, France.
Clin Microbiol Infect ; 27(10): 1494-1501, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1454090
ABSTRACT

OBJECTIVES:

To determine if commercially available mouthwash with ß-cyclodextrin and citrox (bioflavonoids) (CDCM) could decrease the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) salivary viral load.

METHODS:

In this randomized controlled trial, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR-positive patients aged 18-85 years with asymptomatic to mild coronavirus disease 2019 (COVID-19) symptoms for <8 days were recruited. A total of 176 eligible patients were randomly assigned (11) to CDCM or placebo. Three rinses daily were performed for 7 days. Saliva sampling was performed on day 1 at 09.00 (T1), 13.00 (T2) and 18.00 (T3). On the following 6 days, one sample was taken at 15.00. Quantitative RT-PCR was used to detect SARS-CoV-2.

RESULTS:

The intention-to-treat analysis demonstrated that, over the course of 1 day, CDCM was significantly more effective than placebo 4 hours after the first dose (p 0.036), with a median percentage (log10 copies/mL) decrease T1-T2 of -12.58% (IQR -29.55% to -0.16%). The second dose maintained the low median value for the CDCM (3.08 log10 copies/mL; IQR 0-4.19), compared with placebo (3.31 log10 copies/mL; IQR 1.18-4.75). At day 7, there was still a greater median percentage (log10 copies/mL) decrease in salivary viral load over time in the CDCM group (-58.62%; IQR -100% to -34.36%) compared with the placebo group (-50.62%; IQR -100% to -27.66%). These results were confirmed by the per-protocol analysis.

CONCLUSIONS:

This trial supports the relevance of using CDCM on day 1 (4 hours after the initial dose) to reduce the SARS-CoV-2 viral load in saliva. For long-term effect (7 days), CDMC appears to provide a modest benefit compared with placebo in reducing viral load in saliva.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 / Mouthwashes Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 / Mouthwashes Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article